Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 10/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377641 | 0.79 | FFAR1 (0.59) | CYP3A4 | |
| SCHEMBL29602962 | 0.79 | FFAR1 (0.59) | CYP3A4 | |
| SCHEMBL6965067 | 0.77 | CYP3A4 (0.46) | CYP3A4ALOX5MAOBIP6K1MAOA | |
| SCHEMBL6959497 | 0.76 | MAOB (0.55) | CYP3A4ALOX5MAOBMAOA | |
| SCHEMBL6956120 | 0.74 | FFAR1 (0.63) | — | |
| SCHEMBL1746646 | 0.74 | FFAR1 (0.63) | PTPN1MEN1KMT2AHPGD | |
| SCHEMBL305465 | 0.74 | PTPN1 (0.53) | MAOBPTPN1 | |
| SCHEMBL18571362 | 0.73 | CYP3A4 (0.61) | CYP3A4ALOX5MAOBNPC1PDGFRB | |
| SCHEMBL1747427 | 0.73 | FFAR1 (0.52) | PTPN1MEN1KMT2AHPGD | |
| SCHEMBL4940660 | 0.72 | GAA (0.44) | CYP3A4MAOBCA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6121288-A | DECREASING VISCERAL FAT, INHIBITING ACCUMULATION OF VISCERAL FAT AND IMPROVING THE DISTRIBUTION OF VISCERAL FAT BY ADMINISTERING A 5-SUBSTITUTED-2,4-THIAZOLIDINEDIONE DERIVATIVE OF GIVEN FORMULA | NIPPON CHEMIPHAR CO., LTD. (JP) | 2000-09-19 | — | — | US | claimed |
| EP-0974348-A1 | VISCERAL FAT LOWERING AGENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 2000-01-26 | — | — | EP | claimed |
| JP-10182461-A | — | — | None | — | — | JP | disclosed |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | CYMABAY THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | CYMABAY THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-2346498-B1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | JANSSEN PHARMACEUTICA NV (DE) | 2017-10-26 | — | — | US | disclosed |
| US-9724322-B2 | 4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-08 | — | — | US | disclosed |
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | CYMABAY THERAPEUTICS, INC. (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2003080070-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITTOR AND AN INSULIN SECRETOR ENHANCER OR AN INSULIN SENSITIZER | NOVARTIS AG (CH) | 2003-10-02 | — | — | WO | disclosed |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | ORTHO-MCNEIL PHARMACEUITCAL, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002080935-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002080936-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND PPAR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2000073273-A1 | PROCESS FOR THE PREPARATION OF 2-HALO-3-(3-QUINOLYL)PROPIONIC ACID DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 2000-12-07 | — | — | WO | disclosed |
| US-6121288-A | DECREASING VISCERAL FAT, INHIBITING ACCUMULATION OF VISCERAL FAT AND IMPROVING THE DISTRIBUTION OF VISCERAL FAT BY ADMINISTERING A 5-SUBSTITUTED-2,4-THIAZOLIDINEDIONE DERIVATIVE OF GIVEN FORMULA | NIPPON CHEMIPHAR CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-0974348-A1 | VISCERAL FAT LOWERING AGENT | NIPPON CHEMIPHAR CO., LTD. (JP) | 2000-01-26 | — | — | EP | disclosed |
| JP-H10182461-A | VISCERAL FAT REDUCING AGENT | NIPPON CHEMIPHAR CO LTD | 1998-07-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324811-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | CYP3A4 4563/4885ALOX5 570/4885MAOB 1981/4885 |
| US-20190298672-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | CYP3A4 4563/4885ALOX5 570/4885MAOB 1981/4885 |
| US-20190192475-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | CYP3A4 1163/4885ALOX5 672/4885MAOB 4347/4885 |
| US-20230210808-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | CYP3A4 1163/4885ALOX5 672/4885MAOB 4347/4885 |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | GPR119, SLC2A4, SLC2A1 | CYP3A4 1782/4885ALOX5 3653/4885MAOB 3968/4885 |
| US-11007162-B2 | Methods of reducing small, dense LDL particles | LDLR, APOB, HDLBP | CYP3A4 4563/4885ALOX5 570/4885MAOB 1981/4885 |
| US-20030045553-A1 | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators | GPR119, SLC2A4, PPARG | CYP3A4 2012/4885ALOX5 2425/4885MAOB 3427/4885 |
| US-20170304254-A1 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | CYP3A4 1163/4885ALOX5 672/4885MAOB 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.